User:Harrison L. Smith/Sandbox1

This is a default text for your page Harrison L. Smith/Sandbox1. Click above on edit this page to modify. Be careful with the < and > signs.

You may include any references to papers as in: the use of JSmol in Proteopedia ^[1] or to the article describing Jmol ^[2] to the rescue.

Introduction

The insulin receptor is a transmembrane protein receptor that is activated by the binding of insulin and is a vital proponent of cellular function. The insulin receptor belongs to the large class of tyrosine kinase receptors. It plays a key role in a variety of cellular pathways including glucose homeostasis, regulation of lipid, protein, and carbohydrate metabolism, gene expression, and even modulation of brain neurotransmitter levels. This page focuses specifically on the insulin receptor's role in glucose homeostasis.

Structural Highlights

The insulin receptor is a dimer of heterodimers made of two alpha subunits and two beta subunits ^[3]. The is on the extracellular side of the membrane and is critical for binding insulin. There are that have the potential to interact with insulin on the extracellular side of the membrane, but it is generally more common for only one or two insulin molecules to bind to the receptor due to the occurrence of negative affinity at the binding site. The are transmembrane subunits that contain a . Beta chains experience a conformation change that brings them from a V shape to a T shape upon activation or binding of an insulin molecule. When the two subunits are brought near to eachother in the activated T form, each Tyrosine Kinase region autophosphorylates its counterpart at particular Tyrosines.

Function & Structure

Figure 1. An image of the inactive Insulin Receptor Alpha subunit in the inverted V conformation. This image shows only a protomer of the inactive alpha subunit because the entire inactive alpha subunit dimer has been unable to be photographed because the transition state has yet to be determined.

Figure 2. An image of the dimer of an active alpha subunit. The light blue and green areas represent the alpha subunit of the insulin receptor. The magenta, light pink, yellow, and red colorings are the four insulin binding sites with insulin bound.

Figure 3. An image of the active insulin receptor showing both the alpha and beta subunits and insulin bound to the four binding sites. The dimers of the alpha subunit are colored in light blue and green. The intracellular beta sites are colored in blue and orange. The insulin binding sites with insulin bound are colored in magenta, light pink, yellow, and red.

The insulin receptor's function in regards to glucose homeostasis is to begin the signaling pathway that will eventually move glucose transporters to the cell surface which will allow glucose to passively defuse into the cell. The glucose receptor is inactive in the absence of insulin. When insulin does bind to the receptor, it undergoes a conformation change from the inactive inverted V state (Figure 1) to the active T state (Figures 2 and 3). Once activated, the intracellular Beta subunits move together close enough to autophosphorylate, and downstream signaling begins by the phosphorylation of the Insulin Receptor Substrate (IRS).

Structure

The insulin receptor is a receptor tyrosine kinase that exists in two stable conformations, an inactive and active state. The entire insulin receptor is a dimer of heterodimers with two extracellular alpha subunits, and two transmembrane/intracellular beta subunits linked and stabilized by multiple disulfide bonds.

Alpha Subunit

The alpha subunit is the extracellular domain of the insulin receptor and is the site of insulin binding. The alpha subunit is comprised of two Leucine rich domains (L1 & L2), a Cysteine rich domain (CR), and a C-terminal alpha helix. The actual site of insulin binding occurs at the C-terminal alpha helix and is stabilized by the L1 and L2 domains.

Beta Subunit

The beta subunit is the membrane spanning and intracellular portion of the insulin receptor. This domain is composed of three Fibronectin domains (FN III-1,-2,-3) and the tyrosine kinase domain. The tyrosine kinase domain is the site of autophosphorylation upon activation of the receptor.

Conformation Change

The inactive form of the insulin receptor predominates in low-levels of circulating insulin, whereas the active conformation is seen when insulin binds to any of the 4 receptor sites. The inactive conformation resembles an inverted V (Figure 1), and the active conformation resembles a T (Figure 2). Upon the binding of insulin to any of the four binding sites, the conformation change will begin, causing the Beta subunit's tyrosine kinase domains to move close together, allowing them to autophosphorylate. This autophosphorylation is what activates the insulin receptor and allows it to participate in further downstream signaling pathways. ^[4].

Studies have found that optimal insulin receptor activation requires the binding of multiple insulin ligands to two insulin binding sites. In (Figure 3) these two binding sites are colored in magenta and red. Binding of at least one insulin to the red binding site in (Figure 3) is required for the activation of the insulin receptor and the change in conformation to the active T state. ^[5].

Relevance

As mentioned in the Introduction, the insulin receptor is relevant to numerous biological functions of the body. In a healthy, normal-functioning human, each cell has many insulin receptors that reacts to insulin when blood glucose levels rise. Without properly functioning insulin receptors, medical intervention is necessary for survival.

Disease

One of the most common diseases involving the insulin receptor is diabetes mellitus. There are two types of diabetes- which are referred to as type 1 and type 2 diabetes. Type 1 diabetes is classified as "insulin dependent" and is characterized by an inability for the body to produce insulin. This is most often the result of damage or insufficiency in the Islets of Langerhans in the pancreas. Type 2 diabetes is classified as "insulin independent" and is the result of the body producing insufficient amounts of insulin, or not responding to the insulin. This often occurs because of high blood-glucose levels. Both types of diabetes are often treated with insulin injections, and diet and lifestyle changes. ^{[6] [7]}.

Treatment of Diabetes with Insulin